KVUEKenvue Inc.

NYSE www.jnj.com/kenvue/


$ 23.37 $ -0.03 (-0.13 %)    

Wednesday, 18-Sep-2024 10:46:24 EDT
QQQ $ 474.49 $ -0.07 (-0.01 %)
DIA $ 416.40 $ -0.50 (-0.12 %)
SPY $ 563.21 $ -0.65 (-0.12 %)
TLT $ 100.18 $ -0.14 (-0.14 %)
GLD $ 237.53 $ -0.66 (-0.28 %)
$ 23.39
$ 23.40
$ 23.37 x 1,700
$ 23.38 x 200
$ 23.30 - $ 23.50
$ 17.29 - $ 23.55
13,263,749
na
44.8B
$ 0.66
$ 40.03
TBD
na
na ($ 0.03)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-06-2024 06-30-2024 10-Q
2 05-09-2024 03-31-2024 10-Q
3 03-01-2024 12-31-2023 10-K
4 11-03-2023 10-01-2023 10-Q
5 08-02-2023 07-02-2023 10-Q
6 06-02-2023 04-02-2023 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 kenvue-set-to-pop-like-a-tylenol-gelcap-golden-cross-looms-on-stock-chart

Kenvue Inc., owner of major brands like Tylenol, is poised for a technical knockout with a Golden Cross pattern and legal win.

 magnificent-7-miss-out-2-cybersecurity-stocks-stand-firm-retailers-lag-in-volatile-august-here-are-the-top-sp-500-gainers-and-losers

The equity market was volatile in August, with the weakness seen early in the month dissipating amid a rise in rate-cut bets.

 johnson--johnson-spin-off-kenvue-wins-lawsuit-over-pain-killer-tylenol-rapid-release-gelcaps

Kenvue defends against a consumer lawsuit alleging that its Tylenol "Rapid Release" gelcaps did not relieve pain faster...

 shopify-palantir-and-uber-are-among-top-10-large-cap-gainers-last-week-aug-4-aug-10-are-the-others-in-your-portfolio

Top 10 best performing large-cap stocks last week: Shopify, Palantir, Axon, Fortinet, Trade Desk, Natera, SharkNinja, Zillow, A...

 jp-morgan-maintains-overweight-on-kenvue-raises-price-target-to-24

JP Morgan analyst Andrea Teixeira maintains Kenvue (NYSE:KVUE) with a Overweight and raises the price target from $22 to $24.

 deutsche-bank-maintains-buy-on-kenvue-raises-price-target-to-24

Deutsche Bank analyst Steve Powers maintains Kenvue (NYSE:KVUE) with a Buy and raises the price target from $23 to $24.

 rbc-capital-reiterates-outperform-on-kenvue-maintains-24-price-target

RBC Capital analyst Nik Modi reiterates Kenvue (NYSE:KVUE) with a Outperform and maintains $24 price target.

 ubs-maintains-neutral-on-kenvue-raises-price-target-to-22

UBS analyst Peter Grom maintains Kenvue (NYSE:KVUE) with a Neutral and raises the price target from $20 to $22.

 listerine-maker-kenvues-stock-soars-on-strong-q2-sales-from-its-essential-health-unit-reaffirms-annual-guidance

Kenvue sees stock rise following strong Q2 2024 results. Despite a slight dip in sales, revenue of $4 billion beat expectations...

 deutsche-bank-maintains-buy-on-kenvue-lowers-price-target-to-23

Deutsche Bank analyst Steve Powers maintains Kenvue (NYSE:KVUE) with a Buy and lowers the price target from $24 to $23.

 kenvue-boosts-quarterly-cash-dividend-by-25-from-020-to-0205-per-share

The third quarter dividend is payable on August 28, 2024, to shareholders of record as of the close of business on August 14, 2...

 jp-morgan-maintains-overweight-on-kenvue-lowers-price-target-to-22

JP Morgan analyst Andrea Teixeira maintains Kenvue (NYSE:KVUE) with a Overweight and lowers the price target from $23 to $22.

 citigroup-maintains-neutral-on-kenvue-lowers-price-target-to-20

Citigroup analyst Filippo Falorni maintains Kenvue (NYSE:KVUE) with a Neutral and lowers the price target from $21 to $20.

 sanofi-looks-to-sell-20b-icy-hot-division-likely-bidders-include-advent-pai-partners-blackstone-cvc

Sanofi wants $20 billion for its consumer health division, attracting interest from major firms like Advent and PAI Partners.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION